Segment and Geographic Area Information (Tables)

12 Months Ended

Dec. 31, 2015

Segment and Geographic Area Information

Schedule of consolidated financial information by segment

years ended December 31 (in millions)	2015		2014		2013
HUMIRA	$	14,012	$	12,543	$	10,659
IMBRUVICA		754		—		—
VIEKIRA		1,639		48		—
Creon		632		516		412
Synagis		740		835		827
Lupron		826		778		785
Synthroid		755		709		622
Kaletra		700		870		962
AndroGel		694		934		1,035
Sevoflurane		474		550		568
Duodopa		231		220		178
Dyslipidemia products		179		328		1,076
All other		1,223		1,629		1,666
Total net revenues	$	22,859	$	19,960	$	18,790

Schedule of net sales to external customers, based on the country that sold the product

years ended December 31 (in millions)	2015		2014		2013
United States	$	13,561	$	10,845	$	10,181
Germany		1,082		1,035		911
United Kingdom		688		722		606
Spain		618		534		543
Japan		599		581		625
France		597		584		540
Canada		551		551		538
Italy		452		432		404
Brazil		376		435		439
The Netherlands		334		345		332
All other countries		4,001		3,896		3,671
Total net revenues	$	22,859	$	19,960	$	18,790